Monte Rosa Therapeutics, Inc.2024财年第三财季实现净利润-23.86百万美元，同比增加31.59%

市场透视2024-11-16

11月16日，Monte Rosa Therapeutics, Inc.（GLUE.US）公布财报，公告显示公司2024财年第三财季净利润为-23.86百万美元，同比增加31.59%；其中营业收入为9.22百万美元，每股基本收益为-0.29美元。从资产负债表来看，Monte Rosa Therapeutics, Inc.（GLUE.US）总负债1.10亿美元，其中短期债务3.65百万美元，资产负债...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2483306220?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-16 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2483306220","market":"us","top_or_hot":-1,"title":"Monte Rosa Therapeutics, Inc.2024财年第三财季实现净利润-23.86百万美元，同比增加31.59%","media":"市场透视","content":"<div>\n<p>11月16日，Monte Rosa Therapeutics, Inc.（GLUE.US）公布财报，公告显示公司2024财年第三财季净利润为-23.86百万美元，同比增加31.59%；其中营业收入为9.22百万美元，每股基本收益为-0.29美元。从资产负债表来看，Monte Rosa Therapeutics, Inc.（GLUE.US）总负债1.10亿美元，其中短期债务3.65百万美元，资产负债...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116000304abc515e8&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Monte Rosa Therapeutics, Inc.2024财年第三财季实现净利润-23.86百万美元，同比增加31.59%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMonte Rosa Therapeutics, Inc.2024财年第三财季实现净利润-23.86百万美元，同比增加31.59%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-16 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116000304abc515e8&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>11月16日，Monte Rosa Therapeutics, Inc.（GLUE.US）公布财报，公告显示公司2024财年第三财季净利润为-23.86百万美元，同比增加31.59%；其中营业收入为9.22百万美元，每股基本收益为-0.29美元。从资产负债表来看，Monte Rosa Therapeutics, Inc.（GLUE.US）总负债1.10亿美元，其中短期债务3.65百万美元，资产负债...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116000304abc515e8&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116000304abc515e8&s=b","article_id":"2483306220","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116000304abc515e8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2483306220","pubTimestamp":1731686434,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"11月16日，Monte Rosa Therapeutics, Inc.公布财报，公告显示公司2024财年第三财季净利润为-23.86百万美元，同比增加31.59%；其中营业收入为9.22百万美元，每股基本收益为-0.29美元。从资产负债表来看，Monte Rosa Therapeutics, Inc.总负债1.10亿美元，其中短期债务3.65百万美元，资产负债比为2.87，流动比率为0.07。机构评级：截至2024年11月16日，当前有6家机构对Monte Rosa Therapeutics, Inc.目标价做出预测，其中目标均价为15.83美元，其中最低目标价为14.00美元，最高目标价为20.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"LENZ":"Therapeutics","GLUE":"Monte Rosa Therapeutics"},"translate_title":"Monte Rosa Therapeutics, Inc. achieved net profit of-US $23.86 million in the third fiscal quarter of fiscal year 2024, a year-on-year increase of 31.59%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GLUE":1,"LENZ":1},"content_text":"11月16日，Monte Rosa Therapeutics, Inc.（GLUE.US）公布财报，公告显示公司2024财年第三财季净利润为-23.86百万美元，同比增加31.59%；其中营业收入为9.22百万美元，每股基本收益为-0.29美元。从资产负债表来看，Monte Rosa Therapeutics, Inc.（GLUE.US）总负债1.10亿美元，其中短期债务3.65百万美元，资产负债比为2.87，流动比率为0.07。机构评级：截至2024年11月16日，当前有6家机构对Monte Rosa Therapeutics, Inc.目标价做出预测，其中目标均价为15.83美元，其中最低目标价为14.00美元，最高目标价为20.00美元。公司简介：Monte Rosa Therapeutics Inc 是一家生物技术公司，专门开发分子胶降解剂（MGDs），这是一类利用人体天然蛋白质破坏机制选择性降解治疗相关蛋白质的小分子药物。利用 QuEEN 平台，该公司采用人工智能和专有实验工具来识别 MGD 降解的目标蛋白质。拥有超过 50,000 个 MGD 分子的多样化文库，他们最先进的候选产品——MRT-2359，针对可用于 MYC 驱动的肿瘤的，翻译终止因子蛋白 GSPT1。 该公司的重点在于推进其 MGD 产品，旨在为各种疾病提供新颖的治疗方式。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483306220"}